Evaluating only Imara’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Imara founded in Boston to develop PDE9 inhibitors for hemoglobinopathies including sickle cell disease.
FUNDING
Nasdaq IPO raises $74M; IMR-687 enters Phase 2b for sickle cell (ARDENT) and beta-thalassemia simultaneously.
PRODUCT LAUNCH
ARDENT trial reads out; IMR-687 fails primary endpoint of VОС reduction, beta-thalassemia data also disappointing.
SHUTDOWN
Board dissolves company, returns $80M cash to shareholders; all 45 employees laid off.
Full Analysis
Free · no account needed
Documented cause
Imara, a sickle cell disease and beta-thalassemia biotech, shut down in July 2022 after its lead drug tovinontrine (IMR-687) failed Phase 2b trials in both indications. The ARDENT trial for sickle cell showed no significant reduction in vaso-occlusive crises at 24 weeks. CEO Rahul Ballal had raised $165M including a $74M IPO in 2020. Facing zero pipeline and an 18-month cash runway, the board voted to return $80M cash to shareholders rather than pivot.
Lesson
“Dual-indication single-asset strategy doubles your clinical risk; one failure ends everything.”